ARS Pharma Q4 net income $49.9M, neffy sales $6.7M; pediatric approval expands market

ARS Pharmaceuticals, Inc.

neffy net product revenue $7.3M for FY2024 since Sep launch; Q4 net product revenue $6.7M.
FDA approved neffy 1 mg for children 4+ and 15-30 kg on Mar 5, 2025; in pharmacies May 2025.
Cash, equivalents & short-term investments $314M; operating runway at least 3 years.
Payer coverage: >60% commercial lives under contract by end Q1 2025; >80% by early Q3.
Phase 2b trial for chronic urticaria planned Q2 2025; topline data early 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.